Q1 EPS Estimate for Vanda Pharmaceuticals Raised by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research note issued to investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.24) for the quarter, up from their prior forecast of ($0.26). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.36) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The business had revenue of $56.26 million for the quarter, compared to analysts’ expectations of $58.73 million. Vanda Pharmaceuticals had a negative return on equity of 16.82% and a negative net margin of 39.70%.

Other research analysts also recently issued reports about the stock. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 8th. B. Riley boosted their target price on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.63.

Vanda Pharmaceuticals Stock Up 3.3%

VNDA stock opened at $8.13 on Wednesday. The stock has a market cap of $480.48 million, a P/E ratio of -5.73 and a beta of 0.60. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $9.60. The company’s 50 day moving average is $5.81 and its two-hundred day moving average is $5.15.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Vanda Pharmaceuticals by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock worth $17,900,000 after acquiring an additional 14,336 shares during the period. Millennium Management LLC lifted its position in shares of Vanda Pharmaceuticals by 220.0% during the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after purchasing an additional 1,470,898 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Vanda Pharmaceuticals by 4.8% during the second quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after purchasing an additional 77,997 shares in the last quarter. Krensavage Asset Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 15.2% in the third quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after purchasing an additional 155,505 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Vanda Pharmaceuticals by 25.7% during the 3rd quarter. Two Sigma Investments LP now owns 662,305 shares of the biopharmaceutical company’s stock valued at $3,305,000 after purchasing an additional 135,439 shares in the last quarter. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.